Caris Life Sciences, Inc. (CAI) Stock Analysis and Metrics

Caris Life Sciences

NASDAQ: CAI

$15.53 ▼ -0.12 (-0.77%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap4.35 Bn

P/E-10.58

P/S4.80

Div. Yield0.00

ROIC (Qtr)2.11

Total Debt (Qtr)381.25 Mn

Revenue Growth (1y) (Qtr)78.78

Add ratio to table…

About

Caris Life Sciences, Inc. is a patient centric AI driven TechBio company that develops and commercializes precision medicine solutions using comprehensive molecular information and artificial intelligence/machine learning at scale. The company focuses on oncology, offering tissue and blood based genomic profiling services that support early detection, minimal residual disease monitoring, therapy selection, and treatment monitoring. Its proprietary platform integrates next generation sequencing, AI/ML, and high performance computing to generate one of the largest multimodal clinico genomic datasets in cancer.

Caris Life Sciences generates revenue primarily from the sale of its molecular profiling tests and related services to physicians, hospitals, academic centers, and biopharma companies. It also earns income through data licensing agreements that provide deidentified multi modal datasets to external researchers and pharmaceutical partners. Additionally, the company derives revenue from collaborative research and development arrangements with biopharma firms that aim to discover and develop novel therapeutics using its platform.

The company operates through the following segments.

• Molecular Intelligence: This segment provides comprehensive tumor and liquid biopsy profiling, including whole exome, whole transcriptome, and whole genome sequencing solutions such as MI Profile, Caris Assure, and the Precision Whole Genome platform, which support cancer detection, treatment selection, and monitoring.

• Caris Discovery: This segment focuses on drug target and therapeutic discovery, leveraging the company’s profiling data, wet lab facilities, AI/ML tools, and the ADAPT platform to identify novel drug targets and develop therapeutics in partnership with biopharma companies.

• Caris Strategic Data: This segment licenses deidentified multi modal clinico genomic datasets to external researchers and pharmaceutical companies, enabling drug discovery, translational research, and clinical trial design through AI driven analytics.

• Caris Infrastructure: This segment encompasses the company’s laboratory, research, and sales infrastructure, including high throughput sequencing facilities in Phoenix and Tempe, which support scalable testing operations and commercial expansion.

Caris Life Sciences holds a strong position in the precision oncology market, competing with established players such as Foundation Medicine (Roche), Tempus, Guardant Health, and Natera in tissue and liquid biopsy profiling. The company differentiates itself through its patient first approach that delivers deep whole exome and whole transcriptome sequencing, providing industry leading breadth, depth, and accuracy of multi omic information. Its competitive advantages include a large and growing multi modal clinico genomic dataset, a specialized commercial team serving over 6,000 ordering physicians, robust laboratory infrastructure, and deep collaborations with academic centers and biopharma partners.

Caris Life Sciences serves a diverse customer base that includes treating physicians, hospitals, academic cancer centers, and biopharma companies such as Moderna, AbbVie, Xencor, Merck KGaA, and Genentech. The company also works with the members of its Precision Oncology Alliance, a network of leading cancer research institutions, and provides services to over 6,000 ordering physicians across the United States.

Investment Thesis

▲ Bull case

Caris Life Sciences is positioned to capitalize on a structural shift toward comprehensive genomic profiling in oncology, where its MyCancerSEQ assay has become the de facto standard for tissue-based therapy selection, evidenced by its representation of over 75% of tissue volume in Q1 and coverage exceeding 225 million lives. This dominance is not merely a reflection of current market share but indicates a durable competitive moat built on deep clinical validation, extensive data assets (over 1.07 million profiled cases including 677,000 whole exomes), and entrenched relationships with oncologists through its Precision Oncology Alliance, now surpassing 100 members including UC San Francisco. The company’s ability to sustain 61% year-over-year ASP growth—driven by tissue ASP rising 70% to above $4,300—while simultaneously expanding case volumes by 15% demonstrates pricing power rarely seen in diagnostics, suggesting that reimbursement pressure is being offset by superior clinical utility and adoption in complex cases where cheaper alternatives fail to deliver actionable insights. This combination of volume and price strength underpins the margin expansion to 65% GAAP gross margin, up from 47% a year ago, and signals that the business model is leveraging scale effectively, with fixed costs being absorbed by rising throughput without proportional cost increases.
The launch of Caris ChromaSeq for hematological malignancies represents an underappreciated catalyst with significant runway, targeting an addressable market of approximately 50,000 AML, MDS, and MPN patients as defined by MolDX coverage, and priced at $3,228 per test. Unlike many competitors offering fragmented panel tests, ChromaSeq delivers whole-genome sequencing with >200x depth, enabling detection of resistance mechanisms and comprehensive genomic alterations that current standard-of-care approaches miss. Management’s emphasis on the unmet need in myeloid cancers—where patients today receive multiple disparate tests that often miss critical alterations—highlights a clear differentiation opportunity. Furthermore, the assay’s MolDX approval ensures immediate Medicare reimbursement, reducing commercialization risk, and the company is already leveraging its existing MyCancerSEQ payer relationships to accelerate commercial uptake. Given that hematologic malignancies are often diagnosed in community settings where access to advanced testing is limited, Caris’ expanded sales force (now over 270 reps targeting 300) and enhanced training programs are uniquely positioned to penetrate this underserved segment, potentially capturing a meaningful share of the 50,000-patient pool well before competitors can replicate the assay’s technical depth and reimbursement status.
Caris Detect’s ACHIEVE-1 results, showing 60.3% stage 1 and 2 sensitivity and 99.2% asymptomatic specificity in a 3,014-subject high-risk cohort using only one of nine potential biological pillars, reveal a substantial upside option that the market is likely undervaluing. The explicit acknowledgment that performance was generated with a single pillar implies that integrating additional molecular, proteomic, or epigenetic signals could meaningfully boost sensitivity without compromising specificity—a trajectory supported by the company’s foundation of over 50 billion molecular markers from its profiling data. This platform advantage allows for iterative improvements akin to software updates, where each new pillar enhances the AI model’s ability to detect early-stage signals. The planned commercial launch with Everlywell in Q2, coupled with the intent to add channel partners, suggests a deliberate, low-capital go-to-market strategy that minimizes execution risk while testing demand. Moreover, the 135% quarter-over-quarter growth in liquid product specialist targets and the decision to double that team in Q2 indicate strong early traction in blood-based testing, which, when combined with the assay’s high specificity, could drive rapid adoption in screening programs where false positives are particularly costly. The ability to layer Detect onto its existing commercial infrastructure—already processing over 70% of orders electronically and supported by 3,000+ EMR integrations—creates a scalable path to monetization that many pure-play MCED competitors lack.

Caris Life Sciences is positioned to capitalize on a structural shift toward comprehensive genomic profiling in oncology, where its MyCancerSEQ assay has become the de facto standard for tissue-based therapy selection, evidenced by its representation of over 75% of tissue volume in Q1 and coverage exceeding 225 million lives. This dominance is not merely a reflection of current market share but indicates a durable competitive moat built on deep clinical validation, extensive data assets (over 1.07 million profiled cases including 677,000 whole exomes), and entrenched relationships with oncologists through its Precision Oncology Alliance, now surpassing 100 members including UC San Francisco. The company’s ability to sustain 61% year-over-year ASP growth—driven by tissue ASP rising 70% to above $4,300—while simultaneously expanding case volumes by 15% demonstrates pricing power rarely seen in diagnostics, suggesting that reimbursement pressure is being offset by superior clinical utility and adoption in complex cases where cheaper alternatives fail to deliver actionable insights. This combination of volume and price strength underpins the margin expansion to 65% GAAP gross margin, up from 47% a year ago, and signals that the business model is leveraging scale effectively, with fixed costs being absorbed by rising throughput without proportional cost increases.
The launch of Caris ChromaSeq for hematological malignancies represents an underappreciated catalyst with significant runway, targeting an addressable market of approximately 50,000 AML, MDS, and MPN patients as defined by MolDX coverage, and priced at $3,228 per test. Unlike many competitors offering fragmented panel tests, ChromaSeq delivers whole-genome sequencing with >200x depth, enabling detection of resistance mechanisms and comprehensive genomic alterations that current standard-of-care approaches miss. Management’s emphasis on the unmet need in myeloid cancers—where patients today receive multiple disparate tests that often miss critical alterations—highlights a clear differentiation opportunity. Furthermore, the assay’s MolDX approval ensures immediate Medicare reimbursement, reducing commercialization risk, and the company is already leveraging its existing MyCancerSEQ payer relationships to accelerate commercial uptake. Given that hematologic malignancies are often diagnosed in community settings where access to advanced testing is limited, Caris’ expanded sales force (now over 270 reps targeting 300) and enhanced training programs are uniquely positioned to penetrate this underserved segment, potentially capturing a meaningful share of the 50,000-patient pool well before competitors can replicate the assay’s technical depth and reimbursement status.
Caris Detect’s ACHIEVE-1 results, showing 60.3% stage 1 and 2 sensitivity and 99.2% asymptomatic specificity in a 3,014-subject high-risk cohort using only one of nine potential biological pillars, reveal a substantial upside option that the market is likely undervaluing. The explicit acknowledgment that performance was generated with a single pillar implies that integrating additional molecular, proteomic, or epigenetic signals could meaningfully boost sensitivity without compromising specificity—a trajectory supported by the company’s foundation of over 50 billion molecular markers from its profiling data. This platform advantage allows for iterative improvements akin to software updates, where each new pillar enhances the AI model’s ability to detect early-stage signals. The planned commercial launch with Everlywell in Q2, coupled with the intent to add channel partners, suggests a deliberate, low-capital go-to-market strategy that minimizes execution risk while testing demand. Moreover, the 135% quarter-over-quarter growth in liquid product specialist targets and the decision to double that team in Q2 indicate strong early traction in blood-based testing, which, when combined with the assay’s high specificity, could drive rapid adoption in screening programs where false positives are particularly costly. The ability to layer Detect onto its existing commercial infrastructure—already processing over 70% of orders electronically and supported by 3,000+ EMR integrations—creates a scalable path to monetization that many pure-play MCED competitors lack.

▼ Bear case

Caris Life Sciences’ reliance on ASP expansion as a primary driver of revenue growth presents a significant vulnerability, particularly as the 61% year-over-year increase in clinical ASP—driven by tissue ASP rising 70% to above $4,300 and blood ASP growing 14% to just under $2,500—may not be sustainable amid increasing payer scrutiny and the impending PAMA reimbursement review. Although management submitted PAMA data on May 1 and expressed confidence in avoiding downward adjustments, the company’s assays remain classified as CDLTs, subject to PAMA’s three-year reporting and pricing cycle, with any fee schedule update not becoming effective until January 1, 2027. This creates a window of uncertainty where CMS could still impose adjustments based on the submitted data, especially given broader industry pressures under the CRUSH initiative and historical volatility in MolDX pricing for advanced diagnostics. Furthermore, the deceleration in sequential case volume growth—evident in the need to rely on a 10% sequential increase from Q1 to Q2 to reach over 58,000 cases, which management attributes to delayed case completion from Q1 activations—suggests that the underlying demand acceleration may be weaker than implied by the exit run rate. The fact that completed cases came in modestly below initial expectations due to timing, coupled with the need to “catch up” in Q2, raises concerns about whether the sales force realignment from 82 to 146 territories has truly unlocked sustainable demand or merely pulled forward existing pipeline.
The company’s heavy investment in pipeline, while innovative, carries substantial execution and adoption risks that are not being adequately priced in by the market. Caris ChromaSeq, despite MolDX approval and a $3,228 rate, targets a niche hematologic malignancy market of only ~50,000 patients, limiting its near-term revenue impact even if it achieves high penetration. Similarly, Caris MI Clarity, an AI-only digital pathology test for breast cancer recurrence risk, faces steep challenges in displacing established clinical workflows and guidelines, particularly in a disease area already saturated with screening modalities like mammography and genomic assays such as Oncotype DX. The reliance on future product launches to drive growth overlooks the lengthy adoption cycles typical in oncology diagnostics, where reimbursement, physician education, and integration into treatment algorithms can take years. Moreover, the pharma and research revenue decline—down to $5.4 million from $6.8 million year over year—signals potential weakness in its data and discovery business, which management attributes to contractual timing but which could reflect broader industry trends of reduced spending on external biomarker services as pharma companies bring more capabilities in-house. Without a clear path to reaccelerate this segment, the company’s revenue diversification remains fragile.
Caris Detect’s path to commercial success is fraught with unproven assumptions about clinical utility and reimbursement that could undermine its valuation premium. While the ACHIEVE-1 data shows promising sensitivity and specificity, the test’s 60.3% stage 1 and 2 sensitivity—even if improvable with additional pillars—lags behind leading MCED competitors in published studies, raising questions about its real-world effectiveness in asymptomatic populations. More critically, there is no clarity on reimbursement strategy for Caris Detect; unlike ChromaSeq and MyCancerSEQ, which have established MolDX or payer coverage paths, Detect’s pricing, coding, and coverage pathway remain undefined, with management only stating plans for a Q2 launch with Everlywell and no mention of MolDX submission or payer negotiations. This ambiguity is compounded by the fact that MCED tests face significant hurdles in demonstrating mortality reduction in large-scale trials—a requirement for broad payer adoption—and the company has not disclosed any plans for such outcomes research. The decision to launch without a clear reimbursement path risks creating a cash drain if adoption is limited to self-pay or pilot programs, especially given the planned $30 million CapEx for launch preparations and rising OpEx to over $140 million in Q2. Furthermore, the reliance on a single commercial partner (Everlywell) for initial launch increases concentration risk, and the lack of disclosed channel diversification plans suggests the market may be overestimating the speed and scale of Detect’s revenue contribution.

Caris Life Sciences’ reliance on ASP expansion as a primary driver of revenue growth presents a significant vulnerability, particularly as the 61% year-over-year increase in clinical ASP—driven by tissue ASP rising 70% to above $4,300 and blood ASP growing 14% to just under $2,500—may not be sustainable amid increasing payer scrutiny and the impending PAMA reimbursement review. Although management submitted PAMA data on May 1 and expressed confidence in avoiding downward adjustments, the company’s assays remain classified as CDLTs, subject to PAMA’s three-year reporting and pricing cycle, with any fee schedule update not becoming effective until January 1, 2027. This creates a window of uncertainty where CMS could still impose adjustments based on the submitted data, especially given broader industry pressures under the CRUSH initiative and historical volatility in MolDX pricing for advanced diagnostics. Furthermore, the deceleration in sequential case volume growth—evident in the need to rely on a 10% sequential increase from Q1 to Q2 to reach over 58,000 cases, which management attributes to delayed case completion from Q1 activations—suggests that the underlying demand acceleration may be weaker than implied by the exit run rate. The fact that completed cases came in modestly below initial expectations due to timing, coupled with the need to “catch up” in Q2, raises concerns about whether the sales force realignment from 82 to 146 territories has truly unlocked sustainable demand or merely pulled forward existing pipeline.
The company’s heavy investment in pipeline, while innovative, carries substantial execution and adoption risks that are not being adequately priced in by the market. Caris ChromaSeq, despite MolDX approval and a $3,228 rate, targets a niche hematologic malignancy market of only ~50,000 patients, limiting its near-term revenue impact even if it achieves high penetration. Similarly, Caris MI Clarity, an AI-only digital pathology test for breast cancer recurrence risk, faces steep challenges in displacing established clinical workflows and guidelines, particularly in a disease area already saturated with screening modalities like mammography and genomic assays such as Oncotype DX. The reliance on future product launches to drive growth overlooks the lengthy adoption cycles typical in oncology diagnostics, where reimbursement, physician education, and integration into treatment algorithms can take years. Moreover, the pharma and research revenue decline—down to $5.4 million from $6.8 million year over year—signals potential weakness in its data and discovery business, which management attributes to contractual timing but which could reflect broader industry trends of reduced spending on external biomarker services as pharma companies bring more capabilities in-house. Without a clear path to reaccelerate this segment, the company’s revenue diversification remains fragile.
Caris Detect’s path to commercial success is fraught with unproven assumptions about clinical utility and reimbursement that could undermine its valuation premium. While the ACHIEVE-1 data shows promising sensitivity and specificity, the test’s 60.3% stage 1 and 2 sensitivity—even if improvable with additional pillars—lags behind leading MCED competitors in published studies, raising questions about its real-world effectiveness in asymptomatic populations. More critically, there is no clarity on reimbursement strategy for Caris Detect; unlike ChromaSeq and MyCancerSEQ, which have established MolDX or payer coverage paths, Detect’s pricing, coding, and coverage pathway remain undefined, with management only stating plans for a Q2 launch with Everlywell and no mention of MolDX submission or payer negotiations. This ambiguity is compounded by the fact that MCED tests face significant hurdles in demonstrating mortality reduction in large-scale trials—a requirement for broad payer adoption—and the company has not disclosed any plans for such outcomes research. The decision to launch without a clear reimbursement path risks creating a cash drain if adoption is limited to self-pay or pilot programs, especially given the planned $30 million CapEx for launch preparations and rising OpEx to over $140 million in Q2. Furthermore, the reliance on a single commercial partner (Everlywell) for initial launch increases concentration risk, and the lack of disclosed channel diversification plans suggests the market may be overestimating the speed and scale of Detect’s revenue contribution.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password